NOXXON Pharma AG - Product Pipeline Review - 2012 - This pharmaceuticals report, "NOXXON Pharma AG - Product Pipeline Review - 2012" provides data on the NOXXON Pharma AG's research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.
This report is built using data and information sourced from our proprietary databases, NOXXON Pharma AG's corporate website, SEC filings, investor presentations and featured press releases, both from NOXXON Pharma AG and industry-specific third party sources, put together by This team.
Scope
- NOXXON Pharma AG - Brief NOXXON Pharma AG overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of NOXXON Pharma AG human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of NOXXON Pharma AG with complete description of the product's developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the NOXXON Pharma AG's pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.
Reasons to buy
- Evaluate NOXXON Pharma AG's strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of NOXXON Pharma AG in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the NOXXON Pharma AG's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with NOXXON Pharma AG.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of NOXXON Pharma AG and identify potential opportunities in those areas.
Keywords
Current R&D Portfolio of NOXXON Pharma AG; NOXXON Pharma AG - Key Therapeutics; NOXXON Pharma AG - Pipeline Overview and Promising Molecules; NOXXON Pharma AG - News; NOXXON Pharma AG - Latest Updates; NOXXON Pharma AG - Pipeline; NOXXON Pharma AG - Discontinued/Dormant Projects
Table of Contents
Table of Contents
List of Tables
List of Figures
NOXXON Pharma AG Snapshot
NOXXON Pharma AG Overview
Key Information
Key Facts
NOXXON Pharma AG - Research and Development Overview
Key Therapeutic Areas
NOXXON Pharma AG - Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products - Monotherapy
Pipeline Products - Combination Treatment Modalities
NOXXON Pharma AG - Pipeline Products Glance
NOXXON Pharma AG Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
NOXXON Pharma AG - Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
NOXXON Pharma AG - Drug Profiles
NOX-A12
Product Description
Mechanism of Action
R&D Progress
NOX-A12 + Bendamustine + Rituximab
Product Description
Mechanism of Action
R&D Progress
NOX-A12 + Bortezomib + Dexamethasone
Product Description
Mechanism of Action
R&D Progress
NOX-D19
Product Description
Mechanism of Action
R&D Progress
NOX-E36
Product Description
Mechanism of Action
R&D Progress
NOX-G15
Product Description
Mechanism of Action
R&D Progress
NOX-H94
Product Description
Mechanism of Action
R&D Progress
NOX-S93
Product Description
Mechanism of Action
R&D Progress
NOXXON Pharma AG - Pipeline Analysis
NOXXON Pharma AG - Pipeline Products by Therapeutic Class
NOXXON Pharma AG - Pipeline Products By Target
NOXXON Pharma AG - Pipeline Products by Route of Administration
NOXXON Pharma AG - Pipeline Products By Mechanism of Action
NOXXON Pharma AG - Recent Pipeline Updates
NOXXON Pharma AG - Dormant Projects
NOXXON Pharma AG - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
NOXXON Pharma AG, Recent Developments
NOXXON Pharma AG- Press Release
Jul 11, 2012: Noxxon Initiates Phase IIa Study Of Anti-CXCL12/SDF-1 Spiegelmer NOX-A12 For Treatment Of Chronic Lymphocytic Leukemia
Jun 19, 2012: Noxxon Initiates Phase IIa Clinical Trial Of NOX-E36 For Treatment Of Diabetic Nephropathy
Apr 04, 2012: NOXXON's NOX-A12 Delays Glioblastoma Recurrence In Preclinical Model
Nov 02, 2009: NOXXON Announces Initiation Of First-In-Human Clinical Trial With NOX-A12
Oct 12, 2009: NOXXON Pharma Announces Phase I Trial Results For NOX-E36
Sep 03, 2009: NOXXON Is Awarded Research and Development Grant for First-in-Human Clinical Trial with Spiegelmer NOX-A12
Jun 08, 2009: NOXXON Initiates First Clinical Trial With NOX-E36 For Patients With Nephropathy
Financial Deals Landscape
NOXXON Pharma AG, Deals Summary
NOXXON Pharma AG, Pharmaceuticals & Healthcare, Deal Details
Venture Financing
NOXXON Pharma Raises Additional $3 Million In Series D Financing
NOXXON Pharma Secures $50 Million In Series C Financing
Partnerships
NOXXON Pharma Enters Into Co-Development Agreement With Roche
Licensing Agreements
NOXXON Pharma Enters Into Licensing Agreement With Pfizer
NOXXON Pharma Enters Into Licensing Agreement With Eli Lilly
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
NOXXON Pharma AG, Key Information
NOXXON Pharma AG, Key Facts
NOXXON Pharma AG - Pipeline by Indication, 2012
NOXXON Pharma AG - Pipeline by Stage of Development, 2012
NOXXON Pharma AG - Monotherapy Products in Pipeline, 2012
NOXXON Pharma AG - Combination Treatment Modalities in Pipeline, 2012
NOXXON Pharma AG - Phase II, 2012
NOXXON Pharma AG - Pre-Clinical, 2012
NOXXON Pharma AG - Pipeline By Therapeutic Class, 2012
NOXXON Pharma AG - Pipeline By Target, 2012
NOXXON Pharma AG - Pipeline By Route of Administration, 2012
NOXXON Pharma AG - Pipeline Products By Mechanism of Action, 2012
NOXXON Pharma AG - Recent Pipeline Updates, 2012
NOXXON Pharma AG - Dormant Developmental Projects,2012
NOXXON Pharma AG, Other Locations
NOXXON Pharma AG, Deals Summary
NOXXON Pharma Raises Additional $3 Million In Series D Financing
NOXXON Pharma Secures $50 Million In Series C Financing
NOXXON Pharma Enters Into Co-Development Agreement With Roche
NOXXON Pharma Enters Into Licensing Agreement With Pfizer
NOXXON Pharma Enters Into Licensing Agreement With Eli Lilly
List of Figures
NOXXON Pharma AG - Pipeline by Indication, 2012
NOXXON Pharma AG - Pipeline by Stage of Development, 2012
NOXXON Pharma AG - Monotherapy Products in Pipeline, 2012
NOXXON Pharma AG - Combination Treatment Modalities in Pipeline, 2012
NOXXON Pharma AG - Pipeline By Therapeutic Class, 2012
NOXXON Pharma AG - Pipeline By Route of Administration, 2012
NOXXON Pharma AG - Pipeline Products By Mechanism of Action, 2012 30